Stoke Therapeutics Inc Revenue Growth Rates (STOK), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Stoke Therapeutics Inc   (NASDAQ: STOK)
 

STOK's Revenue Growth by Quarter and Year

Stoke Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/STOK/growth
https://api.csimarket.com/api/v1/companies/STOK/fundamentals
https://api.csimarket.com/api/v1/companies/STOK/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
STOK Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 11.26
2nd Quarter June 9.33
1st Quarter March 6.23
FY 26.82





STOK Revenue third quarter 2026 Y/Y Growth Comment
Stoke Therapeutics Inc reported Revenue growth of 5.88% year on year in the third quarter 2026, to $ 11.26 millions, this is lower than Stoke Therapeutics Inc 's recent average Revenue surge of 379.2%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 169 other companies have achieved higher Revenue growth. While Stoke Therapeutics Inc ' s Revenue increase of 5.88% ranks overall at the positon no. 3672 in the third quarter 2026.


STOK Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 5.88 %
2nd Quarter June -32.49 %
1st Quarter March -96.07 %
FY   -

Financial Statements
Stoke Therapeutics Inc 's third quarter 2026 Revenue $ 11.26 millions STOK's Income Statement
Stoke Therapeutics Inc 's third quarter 2025 Revenue $ 10.63 millions Quarterly STOK's Income Statement


STOK Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 20.63 %
2nd Quarter June 49.76 %
1st Quarter March 345 %
FY (Year on Year)   -


Back to STOK Growth rate Comparisons >> Back to STOK Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #170
Healthcare Sector #502
Overall #3672

Revenue Y/Y Growth Statistics
High Average Low
3661.12 % 379.2 % -96.07 %
(Mar 31 2025)   (Jun 30 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #170
Healthcare Sector #502
Overall #3672
Revenue Y/Y Growth Statistics
High Average Low
3661.12 % 379.2 % -96.07 %
(Mar 31 2025)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Stoke Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
601.2 % 85 % -91.29 %
(Mar 31 2025)  


STOK's III. Quarter Q/Q Revenue Comment
Stoke Therapeutics Inc achieved in the III. Quarter 2026 below company average Revenue jump of 20.63% quarter on quarter, to $ 11.26 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -23.08% growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Stoke Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 243.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #66
Overall #243
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #66
Overall #243
Revenue Q/Q Growth Statistics
High Average Low
601.2 % 85 % -91.29 %
(Mar 31 2025)  


STOK's III. Quarter Q/Q Revenue Comment
Stoke Therapeutics Inc achieved in the III. Quarter 2026 below company average Revenue jump of 20.63% quarter on quarter, to $ 11.26 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -23.08% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Stoke Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 243.


Stoke Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 28.21
Y / Y Revenue Growth (TTM) -86.28 %
Year on Year Revenue Growth Overall Ranking # 25
Seqeuential Revenue Change (TTM) 2.26 %
Seq. Revenue Growth (TTM) Overall Ranking # 2109


Cumulative Revenue growth Comment
Stoke Therapeutics Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -86.28% year on year, at Sep 30 2026 compare to the -86.2% decrease at Jun 30 2026. If the Stoke Therapeutics Inc 's fiscal year would end at Sep 30 2026, annual Revenue would be $28 millions.

Among companies within the Healthcare sector 8 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 13 to 25.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 9
Overall # 25

Revenue TTM Y/Y Growth Statistics
High Average Low
2333.81 %
 482.68 %
-86.2 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 103
Sector # 314
S&P 500 # 2109
Cumulative Revenue growth Comment
Stoke Therapeutics Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -86.28% year on year, at Sep 30 2026 compare to the -86.2% decrease at Jun 30 2026. If the Stoke Therapeutics Inc 's fiscal year would end at Sep 30 2026, annual Revenue would be $28 millions.

Among companies within the Healthcare sector 8 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 13 to 25.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 9
Overall # 25

Revenue TTM Y/Y Growth Statistics
High Average Low
2333.81 %
482.68 %
-86.2 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 103
Sector # 314
S&P 500 # 2109




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
STOK's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Livanova Plc10.17%$ 10.170 millions
Kura Oncology Inc 10.07%$ 10.067 millions
Amneal Pharmaceuticals Inc 10.04%$ 10.040 millions
Quest Diagnostics Inc9.98%$ 9.979 millions
Idexx Laboratories Inc9.95%$ 9.950 millions
Bausch Health Companies Inc 9.70%$ 9.698 millions
Marpai Inc9.59%$ 9.586 millions
Haemonetics Corporation9.49%$ 9.492 millions
Progyny Inc 9.08%$ 9.084 millions
Ironwood Pharmaceuticals inc 9.00%$ 8.996 millions
Encompass Health Corporation8.93%$ 8.934 millions
West Pharmaceutical Services Inc 8.73%$ 8.728 millions
Resmed Inc 8.67%$ 8.667 millions
Carlisle Companies Incorporated8.65%$ 8.649 millions
Concentra Group Holdings Parent Inc 8.61%$ 8.611 millions
Merit Medical Systems Inc8.56%$ 8.563 millions
Medpace Holdings Inc 8.50%$ 8.501 millions
Pulmonx Corporation8.47%$ 8.470 millions
Amgen Inc 8.45%$ 8.455 millions
Precipio inc 8.33%$ 8.335 millions
Fulgent Genetics Inc 8.26%$ 8.262 millions
Amphastar Pharmaceuticals Inc 8.22%$ 8.219 millions
Ultragenyx Pharmaceutical Inc 8.17%$ 8.170 millions
Baxter International Inc 8.08%$ 8.078 millions
Tactile Systems Technology Inc 8.07%$ 8.067 millions
Iqvia Holdings Inc 8.00%$ 8.000 millions
Exagen Inc 7.86%$ 7.859 millions
Gyre Therapeutics Inc 7.75%$ 7.754 millions
Stryker Corp7.64%$ 7.644 millions
Bausch and Lomb Corp7.34%$ 7.338 millions


About Stoke Therapeutics Inc Revenue Growth Rates (STOK), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Stoke Therapeutics Inc (CIK 1623526).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-445326
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Stoke Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.